Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
The Breast（2023）
摘要
Image 1
更多查看译文
关键词
Neratinib,Tyrosine kinase inhibitor,HER2-positive,Breast cancer,Early stage,Diarrhea prophylaxis,Dose escalation,Health-related quality of life
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要